[Activity of the ansamycins LM 427 and FCE 22250 on atypical mycobacteria in vitro].
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D004352:Drug Resistance, Microbial; D047029:Lactams, Macrocyclic; D009161:Mycobacterium / Q000187:drug effects*; D009170:Nontuberculous Mycobacteria / Q000187:drug effects*; D017828:Rifabutin; D012293:Rifampin / Q000494:pharmacology; D012294:Rifamycins / Q000494:pharmacology*
D000900:Anti-Bacterial Agents; D047029:Lactams, Macrocyclic; D012294:Rifamycins; D017828:Rifabutin; C041560:FCE 22250; D012293:Rifampin
Attività delle ansamicine LM 427 e FCE 22250 su micobatteri atipici in vitro.